Floatz logo

cd22 car-t

Adult B Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.Cell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Adult B Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
METHOTREXATE
Massachusetts General Hospital
Phase 3BBB
Cytosin-Arabinosid
Massachusetts General Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

cd22 car-t is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell Lymphoma RecurrentDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →